CJC-1295 and Ipamorelin are two growth hormone secretagogue peptides frequently paired in laboratory research examining the body's natural growth hormone signaling pathways.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Research has focused on its ability to stimulate the pituitary gland to increase pulsatile growth hormone release, with a modified structure designed to resist rapid enzymatic breakdown compared to native GHRH.
Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin receptor. Unlike some earlier secretagogues studied in this class, research on Ipamorelin has highlighted its selectivity, showing minimal effects on cortisol, prolactin, or appetite-related hormones in laboratory models.
Why Researchers Study Them Together
CJC-1295 and Ipamorelin act on different receptors within the same growth hormone signaling axis. Combining the two in research protocols allows scientists to study synergistic pulsatile release patterns that neither compound produces alone, making the pairing a common subject of comparative endocrine research.
Key Research Specifications
Purity: Research-grade CJC-1295 and Ipamorelin are typically supplied at greater than 98% purity, verified through HPLC testing.
Form: Both are commonly distributed as lyophilized powder for stability during storage and transport.
Storage: Vials should be kept frozen or refrigerated prior to reconstitution; once mixed, refrigerate and use within the recommended window.
Reconstitution: Bacteriostatic water is the standard diluent used in research settings for both peptides.
Common Research Applications
Pulsatile growth hormone release studies
Pituitary signaling and endocrine axis research
Body composition and metabolic research models
Comparative secretagogue selectivity studies
This article is intended for general research and informational purposes. All products referenced are strictly for laboratory research use only and are not intended for human or animal consumption, diagnosis, or treatment.